A few clinical studies, mainly in children, have presented patients with the STAT1 GOF syndrome treated with the JAK1/2 inhibitor ruxolitinib (n = 33 cases), and the clinical status was generally improved [19–31]. The gene discussed is STAT1; the disease is Down syndrome.